Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Pharmacodynamic Study of Copanlisib (BAY 80-6946) as Monotherapy in Patients With Non-Hodgkin's Lymphoma and Solid Tumors

Next Previous
Trial Profile

A Phase I Pharmacodynamic Study of Copanlisib (BAY 80-6946) as Monotherapy in Patients With Non-Hodgkin's Lymphoma and Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Copanlisib (Primary)
  • Indications Adenoid cystic carcinoma; Advanced breast cancer; Burkitt's lymphoma; Cervical cancer; Diffuse large B cell lymphoma; Endometrial cancer; Follicular lymphoma; Head and neck cancer; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Peripheral T-cell lymphoma; Prostate cancer; Solid tumours; Waldenstrom's macroglobulinaemia
  • Focus Pharmacodynamics
  • Sponsors Bayer

Most Recent Events

  • 24 Mar 2018 Results exploring the relationship between copanlisib pharmacokinetic (PK) and pharmacodynamic (PD) effects in a phase I study in subjects with NHL and solid tumors presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
  • 12 Dec 2017 Results assessing dose dependent pharmacodynamic effects of copanlisib relative to plasma exposure presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
  • 07 Dec 2017 According to a Bayer media release, data from the study will be presented at the 59th Annual Meeting of the American Society of Hematology (ASH).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top